FDMT
FDMT clinical trials: 4D Molecular Therapeutics, Inc.
Every trial on ClinicalTrials.gov where 4D Molecular Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FDMT on the catalyst calendar · FDMT registry changes
- Primary completion Jan 2029Sponsor estimatePhase 3NCT07867080A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).4D Molecular Therapeutics · Diabetic Macular Edema (DME)RecruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT068649884D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics · Macular Neovascularization Secondary to Age-Related Macular DegenerationActive, not recruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD)RecruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1/Phase 2NCT051972704D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration4D Molecular Therapeutics · Neovascular (Wet) Age-Related Macular DegenerationRecruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2029Sponsor estimatePhase 2NCT059305614D-150 in Patients With Diabetic Macular Edema4D Molecular Therapeutics · Diabetic Macular EdemaActive, not recruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT052482304D-710 in Adult Patients With Cystic Fibrosis4D Molecular Therapeutics · Cystic Fibrosis LungRecruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 26, 2027Sponsor estimatePhase 1NCT04483440Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia4D Molecular Therapeutics · ChoroideremiaActive, not recruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 1/Phase 2NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)4D Molecular Therapeutics · X-Linked Retinitis PigmentosaActive, not recruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 1/Phase 2NCT056295594D-310 in Adults With Fabry Disease and Cardiac Involvement4D Molecular Therapeutics · Fabry DiseaseRecruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2026Sponsor estimatePhase 1/Phase 2NCT04519749An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease4D Molecular Therapeutics · Fabry DiseaseActive, not recruitingFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2021ActualNo phase registeredNCT02994368"Natural History" Study of Choroideremia4D Molecular Therapeutics · ChoroideremiaTerminatedFDMTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner